Close

H.C. Wainwright Upgrades Dicerna Pharmaceuticals (DRNA) to Buy

August 15, 2018 7:15 AM EDT
Get Alerts DRNA Hot Sheet
Price: $38.22 --0%

Rating Summary:
    5 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

H.C. Wainwright analyst Ed Arce upgraded Dicerna Pharmaceuticals (NASDAQ: DRNA) from Neutral to Buy with a price target of $21.00 (from $14.00).

Arce said their positive investment rationale is predicated on broad progress across the pipeline. We see three fundamental drivers to our positive view, leading us to upgrade DRNA shares to Buy, from Neutral previously.

(1) Lead drug DCR-PHXC

(2) Second program DCR-HBVS

(3) Several other RNAi programs slated for outlicensing

For an analyst ratings summary and ratings history on Dicerna Pharmaceuticals click here. For more ratings news on Dicerna Pharmaceuticals click here.

Shares of Dicerna Pharmaceuticals closed at $14.82 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Upgrades

Related Entities

H.C. Wainwright, Ed Arce